Abstract
Cancer is the accumulation of genetic and epigenetic events that lead to the disruption of normal cellular development and homeostasis. Skin cancer originates from transformed melanocytes and is one of the few cancers with a significantly increasing incidence. Melanoma, the most aggressive form of skin cancer, accounts for the majority of skin cancer-related deaths, and the 5-year survival rate for late-stage melanoma is under 40%. While having some initial success in the clinic, targeted therapies and immunomodulators have a varied rate of response in patients and typically result in the development of drug resistance. The genomic landscape, including the identification of both driver and passenger mutations, in melanoma is well characterized. The epigenetic events that drive melanoma development and metastasis is an area of active research. The recent appreciation of epigenetic contributions to tumorigenesis focuses on DNA methylation, histone modifications, and noncoding RNAs. Here, we highlight key epigenetic mechanisms and how these epigenetic states can be exploited in (pre)clinical applications leading to novel therapeutic avenues.
This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
References
Albert M, Helin K (2010) Histone methyltransferases in cancer. Semin Cell Dev Biol 21:209–220. https://doi.org/10.1016/j.semcdb.2009.10.007
Bachmann I, Puntervoll H, Otte A, Akslen L (2008) Loss of BMI-1 expression is associated with clinical progress of malignant melanoma. Modern Pathol 21:583–590. https://doi.org/10.1038/modpathol.2008.17
Ball N, Yohn J, Morelli J (1994) RAS mutations in human melanoma: a marker of malignant progression. J Invest Dermatol 102(3):285–290
Barradas M, Anderton E, Acosta J et al (2009) Histone demethylase JMJD3 contributes to epigenetic control of INK4a/ARF by oncogenic RAS. Genes Dev 23:1177–1182. https://doi.org/10.1101/gad.511109
Bartel D (2004) MicroRNAs: genomics, biogenesis, mechanism, and function. Cell 116:281–297
Bemis L, Chen R, Amato C et al (2008) MicroRNA-137 targets microphthalmia-associated transcription factor in melanoma cell lines. Cancer Res 68:1362–1368. https://doi.org/10.1158/0008-5472.CAN-07-2912
Ceol C, Houvras Y, Jane-Valbuena J et al (2011) The histone methyltransferase SETDB1 is recurrently amplified in melanoma and accelerates its onset. Nature 471:513. https://doi.org/10.1038/nature09806
Conway K, Edmiston S, Khondker Z et al (2011) DNA-methylation profiling distinguishes malignant melanomas from benign nevi. Pigment Cell Melanoma Res 24:352–360. https://doi.org/10.1111/j.1755-148X.2011.00828.x
Croce C (2009) Causes and consequences of microRNA dysregulation in cancer. Nat Rev Genet 10:704–714. https://doi.org/10.1038/nrg2634
Dar A, Majid S, Semir D et al (2011) miRNA-205 suppresses melanoma cell proliferation and induces senescence via regulation of E2F1 protein. J Biol Chem 286:16606–16614. https://doi.org/10.1074/jbc.M111.227611
Davies H, Bignell G, Cox C et al (2002) Mutations of the BRAF gene in human cancer. Nature 417:949. https://doi.org/10.1038/nature00766
Esteller M, Corn P, Baylin S, Herman J (2001) A gene hypermethylation profile of human cancer. Cancer Res 61:3225–3229
Fan T, Jiang S, Chung N et al (2011) EZH2-dependent suppression of a cellular senescence phenotype in melanoma cells by inhibition of p21/CDKN1A expression. Mol Cancer Res 9:418–429. https://doi.org/10.1158/1541-7786.MCR-10-0511
Fatemi M, Pao M, Jeong S et al (2005) Footprinting of mammalian promoters: use of a CpG DNA methyltransferase revealing nucleosome positions at a single molecule level. Nucleic Acids Res 33:e176–e176. https://doi.org/10.1093/nar/gni180
Feinberg A, Vogelstein B (1983) Hypomethylation distinguishes genes of some human cancers from their normal counterpart. Nature 301:89–92
Felicetti F, Errico M, Bottero L et al (2008) The promyelocytic leukemia zinc finger–microRNA-221/-222 pathway controls melanoma progression through multiple oncogenic mechanisms. Cancer Res 68: 2745–2754. https://doi.org/10.1158/0008-5472.CAN-07-2538
Figueroa M, Abdel-Wahab O, Lu C et al (2010) Leukemic IDH1 and IDH2 mutations result in a hypermethylation phenotype, disrupt TET2 function, and impair hematopoietic differentiation. Cancer Cell 18:553–567. https://doi.org/10.1016/j.ccr.2010.11.015
Fiziev P, Akdemir K, Miller J et al (2017) Systematic epigenomic analysis reveals chromatin states associated with melanoma progression. Cell Rep 19: 875–889. https://doi.org/10.1016/j.celrep.2017.03.078
Freedberg D, Rigas S, Russak J et al (2008) Frequent p16-independent inactivation of p14 ARF in human melanoma. Jnci J Natl Cancer Inst 100:784–795. https://doi.org/10.1093/jnci/djn157
Gallagher S, Gunatilake D, Beaumont K et al (2018) HDAC inhibitors restore BRAF-inhibitor sensitivity by altering PI3K and survival signalling in a subset of melanoma. Int J Cancer 142:1926–1937. https://doi.org/10.1002/ijc.31199
Garraway L, Widlund H, Rubin M et al (2005) Integrative genomic analyses identify MITF as a lineage survival oncogene amplified in malignant melanoma. Nature 436:117. https://doi.org/10.1038/nature03664
Gide T, Wilmott J, Scolyer R, Long G (2017) Primary and acquired resistance to immune checkpoint inhibitors in metastatic melanoma. Clin Cancer Res 24:1260–1270. https://doi.org/10.1158/1078-0432.CCR-17-2267
Gollob J, Sciambi C, Peterson B et al (2006) Phase I trial of sequential low-dose 5-Aza-2′-deoxycytidine plus high-dose intravenous bolus interleukin-2 in patients with melanoma or renal cell carcinoma. Clin Cancer Res 12:4619–4627. https://doi.org/10.1158/1078-0432.CCR-06-0883
Gonzalgo M, Bender C, You E et al (1997) Low frequency of p16/CDKN2A methylation in sporadic melanoma: comparative approaches for methylation analysis of primary tumors. Cancer Res 57:5336–5347
Greger V, Passarge E, Hopping W, Messmer E, Horsthemke B (1989) Epigenetic changes may contribute to the formation and spontaneous regression of retinoblastoma. Hum Genet 83:155–158
Gupta R, Shah N, Wang K et al (2010) Long non-coding RNA HOTAIR reprograms chromatin state to promote cancer metastasis. Nature 464:1071. https://doi.org/10.1038/nature08975
Haas N, Quirt I, Hotte S et al (2014) Phase II trial of vorinostat in advanced melanoma. Invest New Drug 32:526–534. https://doi.org/10.1007/s10637-014-0066-9
Hesson L, Cooper W, Latif F (2007) The role of RASSF1A methylation in cancer. Dis Markers 23:73–87
Hodi F, O’Day S, McDermott D et al (2010) Improved survival with ipilimumab in patients with metastatic melanoma. New Engl J Med 363:711–723. https://doi.org/10.1056/NEJMoa1003466
Hodis E, Watson IR, Kryukov GV et al (2012) A landscape of driver mutations in melanoma. Cell 150:251–263. https://doi.org/10.1016/j.cell.2012.06.024
Hoon D, Spugnardi M, Kuo C et al (2004) Profiling epigenetic inactivation of tumor suppressor genes in tumors and plasma from cutaneous melanoma patients. Oncogene 23:4014. https://doi.org/10.1038/sj.onc.1207505
Huarte M (2015) The emerging role of lncRNAs in cancer. Nat Med 21:1253. https://doi.org/10.1038/nm.3981
Ibrahim N, Buchbinder E, Granter S et al (2016) A phase I trial of panobinostat (LBH589) in patients with metastatic melanoma. Cancer Med-US 5:3041–3050. https://doi.org/10.1002/cam4.862
Jin S, Xiong W, Wu X, Yang L, Pfeifer G (2016) The DNA methylation landscape of human melanoma. Genomics 106:322–330. https://doi.org/10.1016/j.ygeno.2015.09.004
Kadoch C, Hargreaves D, Hodges C et al (2013) Proteomic and bioinformatic analysis of mammalian SWI/SNF complexes identifies extensive roles in human malignancy. Nat Genet 45:592–601. https://doi.org/10.1038/ng.2628
Kapoor A, Goldberg M, Cumberland L et al (2010) The histone variant macroH2A suppresses melanoma progression through regulation of CDK8. Nature 468:1105. https://doi.org/10.1038/nature09590
Khaitan D, Dinger M, Mazar J et al (2011) The melanoma-upregulated long noncoding RNA SPRY4-IT1 modulates apoptosis and invasion. Cancer Res 71: 3852–3862. https://doi.org/10.1158/0008-5472.CAN-10-4460
Koga Y, Pelizzola M, Cheng E et al (2009) Genome-wide screen of promoter methylation identifies novel markers in melanoma. Genome Res 19:1462–1470. https://doi.org/10.1101/gr.091447.109
Konieczkowski D, Johannessen C, Garraway L (2018) A convergence-based framework for cancer drug resistance. Cancer Cell 33:801–815
Lahtz C, Stranzenbach R, Fiedler E et al (2010) Methylation of PTEN as a prognostic factor in malignant melanoma of the skin. J Invest Dermatol 130:620–622. https://doi.org/10.1038/jid.2009.226
Lauss M, Haq R, Cirenajwis H et al (2015) Genome-wide DNA methylation analysis in melanoma reveals the importance of CpG methylation in MITF regulation. J Invest Dermatol 135:1820–1828. https://doi.org/10.1038/jid.2015.61
Li P, He Q, Luo C, Qian (2014) Circulating miR-221 expression level and prognosis of cutaneous malignant melanoma. Med Sci Monit 20:2472–2477. https://doi.org/10.12659/MSM.891327
Lian CG, Xu Y, Ceol C et al (2012) Loss of 5-hydroxymethylcytosine is an epigenetic hallmark of melanoma. Cell 150:1135–1146. https://doi.org/10.1016/j.cell.2012.07.033
Mann B, Johnson J, Cohen M et al (2007) FDA approval summary: vorinostat for treatment of advanced primary cutaneous T-cell lymphoma. Oncologist 12: 1247–1252. https://doi.org/10.1634/theoncologist.12-10-1247
Marzese D, Scolyer R, Huynh J et al (2014) Epigenome-wide DNA methylation landscape of melanoma progression to brain metastasis reveals aberrations on homeobox D cluster associated with prognosis. Hum Mol Genet 23:226–238. https://doi.org/10.1093/hmg/ddt420
Mirmohammadsadegh A, Marini A, Nambiar S et al (2006) Epigenetic silencing of the PTEN gene in melanoma. Cancer Res 66:6546–6552. https://doi.org/10.1158/0008-5472.CAN-06-0384
Munster P, Marchion D, Thomas S et al (2009) Phase I trial of vorinostat and doxorubicin in solid tumours: histone deacetylase 2 expression as a predictive marker. Brit J Cancer 101:1044. https://doi.org/10.1038/sj.bjc.6605293
Network T, Akbani R, Akdemir K et al (2015) Genomic classification of cutaneous melanoma. Cell 161: 1681–1696. https://doi.org/10.1016/j.cell.2015.05.044
Raj K, Mufti G (2006) Azacytidine (Vidaza®) in the treatment of myelodysplastic syndromes. Ther Clin Risk Manag 2:377–388. https://doi.org/10.2147/tcrm.2006.2.4.377
Rauch T, Pfeifer G (2010) DNA methylation profiling using the methylated-CpG island recovery assay (MIRA). Methods 52:213–217. https://doi.org/10.1016/j.ymeth.2010.03.004
Robert C, Karaszewska B, Schachter J et al (2015) Improved overall survival in melanoma with combined dabrafenib and trametinib. New Engl J Med 372:30–39. https://doi.org/10.1056/NEJMoa1412690
Saba H (2007) Decitabine in the treatment of myelodysplastic syndromes. Ther Clin Risk Manag 3(5):807–817
Segura M, Hanniford D, Menendez S et al (2009) Aberrant miR-182 expression promotes melanoma metastasis by repressing FOXO3 and microphthalmia-associated transcription factor. Proc Natl Acad Sci 106: 1814–1819. https://doi.org/10.1073/pnas.0808263106
Segura M, Fontanals-Cirera B, Gaziel-Sovran A et al (2013) BRD4 sustains melanoma proliferation and represents a new target for epigenetic therapy. Cancer Res 73:6264–6276. https://doi.org/10.1158/0008-5472.CAN-13-0122-T
Siegel RL, Miller K, Jemal A (2018) Cancer statistics, 2018. CA Cancer J Clin 68(1):7–30. https://doi.org/10.3322/caac.21442
Sigalotti L, Fratta E, Coral S et al (2004) Intratumor heterogeneity of cancer/testis antigens expression in human cutaneous melanoma is methylation-regulated and functionally reverted by 5-Aza-2′-deoxycytidine. Cancer Res 64:9167–9171
Song F, Amos C, Lee J et al (2014) Identification of a melanoma susceptibility locus and somatic mutation in TET2. Carcinogenesis 35:2097–2101. https://doi.org/10.1093/carcin/bgu140
Spugnardi M, Tommasi, Dammann R, Pfeifer G, Hoon D (2003) Epigenetic inactivation of RAS association domain family protein 1 (RASSF1A) in malignant cutaneous melanoma. Cancer Res 63:1639–1643
Steingrimsson E, Copeland N, Jenkins N (2004) Melanocytes and the microthalmia transcription factor network. Annu Rev Genet 38:365–411
Straume O, Smeds J, Kumar R, Hemminki K, Akslen L (2002) Significant impact of promoter hypermethylation and the 540 C>T polymorphism of CDKN2A in cutaneous melanoma of the vertical growth phase. Am J Pathol 161:229–237
Strub T, Ghiraldini F, Carcamo S et al (2018) SIRT6 haploinsufficiency induces BRAFV600E melanoma cell resistance to MAPK inhibitors via IGF signalling. Nat Commun 9:3440. https://doi.org/10.1038/s41467-018-05966-z
Szyt M, Pakneshan P, Rabbani S (2004) DNA demethylation and cancer: therapeutic implications. Cancer Lett 211:133–143
Tahiliani M, Koh K, Shen Y et al (2009) Conversion of 5-methylcytosine to 5-hydroxymethylcytosine in mammalian DNA by MLL partner TET1. Science 324:930–935. https://doi.org/10.1126/science.1170116
Tang L, Zhang W, Su B, Yu B (2013) Long noncoding RNA HOTAIR is associated with motility, invasion, and metastatic potential of metastatic melanoma. Biomed Res Int 2013:1–7. https://doi.org/10.1155/2013/251098
Vardabasso C, Gaspar-Maia A, Hasson D et al (2015) Histone variant H2A.Z.2 mediates proliferation and drug sensitivity of malignant melanoma. Mol Cell 59:75–88. https://doi.org/10.1016/j.molcel.2015.05.009
Ward P, Patel J, Wise D et al (2010) The common feature of leukemia-associated IDH1 and IDH2 mutations is a neomorphic enzyme activity converting α-ketoglutarate to 2-hydroxyglutarate. Cancer Cell 17:225–234. https://doi.org/10.1016/j.ccr.2010.01.020
Wolchok J, Chiarion-Sileni V, Gonzalez R et al (2017) Overall survival with combined nivolumab and ipilimumab in advanced melanoma. New Engl J Med 377:1345–1356. https://doi.org/10.1056/NEJMoa1709684
Xu W, Yang H, Liu Y et al (2011) Oncometabolite 2-hydroxyglutarate is a competitive inhibitor of α-ketoglutarate-dependent dioxygenases. Cancer Cell 19:17–30. https://doi.org/10.1016/j.ccr.2010.12.014
Zakharia Y, Monga V, Swami U et al (2017) Targeting epigenetics for treatment of BRAF mutated metastatic melanoma with decidibine in combination with vemurafenib: a phase 1b study. Oncotarget 8(51):89182–89193. https://doi.org/10.18632/oncotarget.21269
Zhang H, Cai K, Wang J et al (2014) MiR-7, inhibited indirectly by LincRNA HOTAIR, directly inhibits SETDB1 and reverses the EMT of breast cancer stem cells by downregulating the STAT3 pathway. Stem Cells 32:2858–2868. https://doi.org/10.1002/stem.1795
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Section Editor information
Rights and permissions
Copyright information
© 2019 Springer Science+Business Media, LLC, part of Springer Nature
About this entry
Cite this entry
Dang, M., Zon, L. (2019). Epigenetic Regulation in Melanoma. In: Fisher, D., Bastian, B. (eds) Melanoma. Springer, New York, NY. https://doi.org/10.1007/978-1-4614-7147-9_42
Download citation
DOI: https://doi.org/10.1007/978-1-4614-7147-9_42
Published:
Publisher Name: Springer, New York, NY
Print ISBN: 978-1-4614-7148-6
Online ISBN: 978-1-4614-7147-9
eBook Packages: MedicineReference Module Medicine